ATE245442T1 - Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose - Google Patents

Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose

Info

Publication number: ATE245442T1
Authority: AT; Austria
Prior art keywords: dried preparation; containing trehalose; blood factors; factors containing; trehalose
Prior art date: 1995-01-19

Application number

AT96900633T

Other languages

English (en)

Inventor

Bruce Joseph Roser

Original Assignee

Elan Drug Delivery Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-19

Filing date

1996-01-19

Publication date

2003-08-15

1996-01-19 Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd

2003-08-15 Application granted granted Critical

2003-08-15 Publication of ATE245442T1 publication Critical patent/ATE245442T1/de

Links

HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 title abstract 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 title abstract 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 title abstract 2
229960000182 blood factors Drugs 0.000 title abstract 2
102000008100 Human Serum Albumin Human genes 0.000 abstract 1
108091006905 Human Serum Albumin Proteins 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000003019 stabilising effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT96900633T 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose ATE245442T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9501040.1A GB9501040D0 (en)	1995-01-19	1995-01-19	Dried composition
PCT/GB1996/000119 WO1996022107A1 (en)	1995-01-19	1996-01-19	Dried blood factor composition comprising trehalose

Publications (1)

Publication Number	Publication Date
ATE245442T1 true ATE245442T1 (de)	2003-08-15

Family

ID=10768253

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT03002147T ATE413885T1 (de)	1995-01-19	1996-01-19	Getrocknete blutfaktorzusammensetzung mit trehalose
AT96900633T ATE245442T1 (de)	1995-01-19	1996-01-19	Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT03002147T ATE413885T1 (de)	1995-01-19	1996-01-19	Getrocknete blutfaktorzusammensetzung mit trehalose

Country Status (15)

Country	Link
US (2)	US6649386B2 (de)
EP (4)	EP0871476B1 (de)
JP (1)	JP3898221B2 (de)
KR (1)	KR100417593B1 (de)
CN (1)	CN1152713C (de)
AT (2)	ATE413885T1 (de)
AU (1)	AU704317B2 (de)
CA (2)	CA2210872C (de)
DE (2)	DE69637749D1 (de)
DK (2)	DK1308170T3 (de)
ES (2)	ES2316658T3 (de)
GB (1)	GB9501040D0 (de)
PT (2)	PT1308170E (de)
SI (1)	SI1308170T1 (de)
WO (1)	WO1996022107A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7244824B2 (en) *	1995-01-19	2007-07-17	Quadrant Drug Delivery Limited	Dried blood factor composition comprising trehalose
US7253262B2 (en) *	1995-01-19	2007-08-07	Quandrant Drug Delivery Limited	Dried blood factor composition comprising trehalose
GB9501040D0 (en) *	1995-01-19	1995-03-08	Quadrant Holdings Cambridge	Dried composition
US6964771B1 (en)	1995-06-07	2005-11-15	Elan Drug Delivery Limited	Method for stably incorporating substances within dry, foamed glass matrices
US6632648B1 (en) *	1996-05-14	2003-10-14	Elan Drug Delivery Limited	Methods of terminal sterilization of fibrinogen
GB9616536D0 (en) *	1996-08-06	1996-09-25	Quadrant Holdings Cambridge	Co-amoxiclav dosage form
AUPO871997A0 (en) *	1997-08-25	1997-09-18	Csl Limited	Dried biologically or therapeutically active preparations
CA2634663C (en) *	1999-02-22	2009-08-25	University Of Connecticut	Novel albumin-free factor viii formulations
JP4340151B2 (ja) *	2001-08-10	2009-10-07	株式会社林原生物化学研究所	トレハロース又はマルチトールと金属イオン化合物との会合物
EP2289547B1 (de)	2003-09-12	2015-12-16	Agenus Inc.	Impfstoff zur Behandlung und Prävention der Herpes Simplex-Virusinfektion
US7425539B2 (en)	2004-03-19	2008-09-16	Baxter International Inc.	Factor IXa for the treatment of bleeding disorders
JP2008509226A (ja)	2004-05-24	2008-03-27	ジェンボールトコーポレイション	回収可能な形式での安定なタンパク質保管および安定な核酸保管
KR100624013B1 (ko)	2004-06-25	2006-09-19	주식회사 녹십자홀딩스	동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US8133484B2 (en)	2006-12-15	2012-03-13	Lifebond Ltd	Hemostatic materials and dressing
EP2114379A2 (de) *	2006-12-20	2009-11-11	Bayer HealthCare LLC	Faktor-vi- und -viia-zusammensetzungen
EP1958618A1 (de) *	2007-02-15	2008-08-20	Octapharma AG	Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
AU2008340304B2 (en) *	2007-12-21	2016-03-03	Aptevo Biotherapeutics Llc	Stabilized factor IX formulations containing trehalose
US11197916B2 (en)	2007-12-28	2021-12-14	Takeda Pharmaceutical Company Limited	Lyophilized recombinant VWF formulations
WO2009086400A2 (en) *	2007-12-28	2009-07-09	Baxter International Inc.	Recombinant vwf formulations
CN102177237B (zh)	2008-09-12	2013-10-30	金沃特公司	用于贮存和稳定生物分子的基质和介质
DK2349314T3 (da) *	2008-10-21	2013-05-27	Baxter Int	Lyofiliserede præparater af rekombinant VWF
EP2385825B1 (de)	2008-11-07	2018-10-10	University of Connecticut	Faktor-viii-formulierungen
JP5796860B2 (ja)	2009-12-22	2015-10-21	ライフボンドリミテッドＬｉｆｅｂｏｎｄＬｔｄ	架橋マトリックスの特性を調節するための酵素的架橋剤の改変
EP2732262A4 (de) *	2011-07-13	2014-12-10	Denator Ab	Verfahren zur stabilisierung von flüssigen biologischen proben
CN102416171B (zh) *	2011-12-06	2013-12-25	中国医学科学院输血研究所	高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂
US9700486B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN105899220B (zh) *	2013-12-19	2020-01-10	扬森疫苗与预防公司	改进的病毒体配制品
JP6516829B2 (ja)	2014-08-04	2019-05-22	シーエスエル、リミテッド	第ｖｉｉｉ因子製剤
EP3294324A1 (de)	2015-05-13	2018-03-21	Agenus Inc.	Impfstoffe zur behandlung und prävention von krebs
CN107333750A (zh) *	2017-06-11	2017-11-10	成都吱吖科技有限公司	一种长时血液细胞稳定剂
KR20210005646A (ko)	2018-04-26	2021-01-14	아게누스 인코포레이티드	열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
US11998654B2 (en)	2018-07-12	2024-06-04	Bard Shannon Limited	Securing implants and medical devices
KR20220029733A (ko)	2019-07-04	2022-03-08	체에스엘 베링 렝나우 아게	응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
EP4240757A2 (de)	2020-11-09	2023-09-13	Takeda Pharmaceutical Company Limited	Reinigung von fviii aus plasma mittels siliciumoxidadsorption
WO2022261716A1 (en) *	2021-06-16	2022-12-22	Exopharm Limited	Aqueous formulations for preservation of extracellular vesicles
WO2024102796A2 (en) *	2022-11-08	2024-05-16	University Of Wyoming	Stabilization of biologics and human blood clotting factor viii in a dry state

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4361509A (en)	1981-12-14	1982-11-30	Scripps Clinic And Research Foundation	Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) *	1982-08-05	1985-01-22	University Of Rochester	Preparation of highly purified human antihemophilic factor
IL74909A (en)	1984-04-20	1992-01-15	Genentech Inc	Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
EP0182448A3 (de)	1984-08-24	1987-10-28	Genetics Institute, Inc.	Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
ATE68524T1 (de) *	1985-07-09	1991-11-15	Quadrant Bioresources Ltd	Beschuetzung von proteinen und aehnlichem.
US4758657A (en) *	1985-07-11	1988-07-19	Armour Pharmaceutical Company	Method of purifying Factor VIII:C
US4806343A (en) *	1986-03-13	1989-02-21	University Of Southwestern Louisiana	Cryogenic protectant for proteins
CA1329760C (en) *	1987-10-29	1994-05-24	Ted C. K. Lee	Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) *	1987-11-09	1989-10-31	Rorer Pharmaceutical Corporation	Pharmaceutical plasma protein formulations in low ionic strength media
AU650045B2 (en) *	1990-09-12	1994-06-09	Lifecell Corporation	Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
DE4111393A1 (de) *	1991-04-09	1992-10-15	Behringwerke Ag	Stabilisierte faktor viii-praeparationen
US5288853A (en) *	1992-04-30	1994-02-22	Alpha Therapeutic Corporation	Factor viii purification process
WO1994007510A1 (en) *	1992-10-02	1994-04-14	Kabi Pharmacia Ab	Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
SE504074C2 (sv)	1993-07-05	1996-11-04	Pharmacia Ab	Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU7254894A (en) *	1993-07-23	1995-02-20	Baxter International Inc.	Activated human factor viii and method of preparation
US5576291A (en) *	1993-09-13	1996-11-19	Baxter International Inc.	Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5955448A (en) *	1994-08-19	1999-09-21	Quadrant Holdings Cambridge Limited	Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
GB9501040D0 (en) *	1995-01-19	1995-03-08	Quadrant Holdings Cambridge	Dried composition
US7253262B2 (en) *	1995-01-19	2007-08-07	Quandrant Drug Delivery Limited	Dried blood factor composition comprising trehalose
US5804420A (en) *	1997-04-18	1998-09-08	Bayer Corporation	Preparation of recombinant Factor VIII in a protein free medium
CA2634663C (en) *	1999-02-22	2009-08-25	University Of Connecticut	Novel albumin-free factor viii formulations

1995
- 1995-01-19 GB GBGB9501040.1A patent/GB9501040D0/en active Pending
1996
- 1996-01-19 ES ES03002147T patent/ES2316658T3/es not_active Expired - Lifetime
- 1996-01-19 EP EP96900633A patent/EP0871476B1/de not_active Expired - Lifetime
- 1996-01-19 PT PT03002147T patent/PT1308170E/pt unknown
- 1996-01-19 CN CNB961926600A patent/CN1152713C/zh not_active Expired - Lifetime
- 1996-01-19 DK DK03002147T patent/DK1308170T3/da active
- 1996-01-19 CA CA002210872A patent/CA2210872C/en not_active Expired - Lifetime
- 1996-01-19 DK DK96900633T patent/DK0871476T3/da active
- 1996-01-19 WO PCT/GB1996/000119 patent/WO1996022107A1/en not_active Ceased
- 1996-01-19 SI SI9630765T patent/SI1308170T1/sl unknown
- 1996-01-19 DE DE69637749T patent/DE69637749D1/de not_active Expired - Lifetime
- 1996-01-19 EP EP08010169A patent/EP1974741A1/de not_active Withdrawn
- 1996-01-19 AT AT03002147T patent/ATE413885T1/de active
- 1996-01-19 AU AU44540/96A patent/AU704317B2/en not_active Expired
- 1996-01-19 EP EP03002147A patent/EP1308170B1/de not_active Expired - Lifetime
- 1996-01-19 JP JP52213396A patent/JP3898221B2/ja not_active Expired - Fee Related
- 1996-01-19 US US08/875,796 patent/US6649386B2/en not_active Expired - Lifetime
- 1996-01-19 AT AT96900633T patent/ATE245442T1/de active
- 1996-01-19 DE DE69629209T patent/DE69629209T2/de not_active Expired - Lifetime
- 1996-01-19 CA CA2671383A patent/CA2671383C/en not_active Expired - Lifetime
- 1996-01-19 PT PT96900633T patent/PT871476E/pt unknown
- 1996-01-19 EP EP10008828A patent/EP2258402A3/de not_active Withdrawn
- 1996-01-19 KR KR1019970704891A patent/KR100417593B1/ko not_active Expired - Lifetime
- 1996-01-19 ES ES96900633T patent/ES2202425T3/es not_active Expired - Lifetime
2009
- 2009-02-13 US US12/371,459 patent/US7803911B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20090149388A1 (en)	2009-06-11
JP3898221B2 (ja)	2007-03-28
PT1308170E (pt)	2008-12-26
EP1308170A2 (de)	2003-05-07
EP0871476A1 (de)	1998-10-21
DK0871476T3 (da)	2003-11-10
US20020128207A1 (en)	2002-09-12
EP2258402A3 (de)	2011-01-05
DE69629209T2 (de)	2004-02-19
DE69637749D1 (de)	2008-12-24
PT871476E (pt)	2003-12-31
EP1974741A1 (de)	2008-10-01
DE69629209D1 (de)	2003-08-28
CN1152713C (zh)	2004-06-09
CA2210872A1 (en)	1996-07-25
ES2316658T3 (es)	2009-04-16
CA2671383A1 (en)	1996-07-25
EP1308170A3 (de)	2004-03-03
AU704317B2 (en)	1999-04-22
SI1308170T1 (sl)	2009-04-30
CA2210872C (en)	2009-09-08
GB9501040D0 (en)	1995-03-08
KR100417593B1 (ko)	2004-04-30
WO1996022107A1 (en)	1996-07-25
JPH11503719A (ja)	1999-03-30
AU4454096A (en)	1996-08-07
ES2202425T3 (es)	2004-04-01
CA2671383C (en)	2012-04-24
EP1308170B1 (de)	2008-11-12
EP2258402A2 (de)	2010-12-08
KR19980701500A (ko)	1998-05-15
US6649386B2 (en)	2003-11-18
ATE413885T1 (de)	2008-11-15
US7803911B2 (en)	2010-09-28
EP0871476B1 (de)	2003-07-23
DK1308170T3 (da)	2008-12-15
CN1179107A (zh)	1998-04-15

Legal Events

Date

Code

Title

Description

2004-04-15

UEP

Publication of translation of european patent specification

Ref document number: 0871476

Country of ref document: EP

2004-08-15

EEFA

Change of the company name

Publication	Publication Date	Title
DE69629209D1 (de)	2003-08-28	Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
MX9304710A (es)	1994-05-31	Composicion farmaceutica y/o cosmetica y su uso.
NO179911C (no)	1997-01-08	Optisk aktivt 5H-pyrrolo[3,4-bÅpyrazinderivat samt farmasöytiske preparater inneholdende derivatet
DE3785684D1 (de)	1993-06-09	Pyrrolidinamid-derivate von acylaminosaeure, pharmazeutische zusammensetzung und verwendung.
DE3777850D1 (de)	1992-05-07	Eine persauerstoffverbindung enthaltende, konzentrierte, fluessige zusammensetzungen.
ATE105297T1 (de)	1994-05-15	Derivate von 2'-halomethyliden, 2'-ethenyliden und 2'-ethynylcytidin, uridin und guanosin.
ATE82857T1 (de)	1992-12-15	Interleukin-2-zusammensetzungen.
ATE92542T1 (de)	1993-08-15	Azeotropaehnliche zusammensetzungen von 1,1dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1fluor\|than.
DE3576505D1 (de)	1990-04-19	3,4-dihydrobenzopyranverbindungen und diese enthaltende pharmazeutische zusammenstellungen.
DE59208622D1 (de)	1997-07-24	Dentalwerkstoffe auf Basis von (Meth)-Acrylaten
DK0453603T3 (da)	1993-11-22	Piroxicamholdige farmaceutiske præparater til topisk anvendelse
ATE104554T1 (de)	1994-05-15	Topische praeparate.
DE69208681D1 (de)	1996-04-04	Verwendungen von 1,1,1,3,3,3-hexafluoropropan
FI923751A0 (fi)	1992-08-20	Hexahydrobenso/f/kinolinoner.
IT8520234A0 (it)	1985-04-04	Composizione farmaceutiche adattivita' dopominergica.
ATE26109T1 (de)	1987-04-15	Acetylcystein-salze, ihre herstellung und verwendung.
IL85517A (en)	1992-09-06	3-(2-haloethyl)1,4-oxathiin and 2-(2-haloethyl)1,4-dithiin derivatives and pharmaceutical compositions containing the same
DE59107240D1 (de)	1996-02-22	Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
DE68912432D1 (de)	1994-03-03	Pharmazeutische Zusammensetzung, verwendbar bei der Behandlung von Herzgefässerkrankungen.
IT1237087B (it)	1993-05-18	N,n'-di-(trimetossibenzoil) piperazine 2-metossicarbonil sostituite, procedimento per preparare le stesse e composti terapeutici che le contengono.
DE3869232D1 (de)	1992-04-23	Abkoemmlinge von bornan-3-spiro-l'-cyclopentan und diese enthaltende riechstoffzusammensetzungen.
IT1215261B (it)	1990-01-31	Composizioni farmaceutiche adattivita' antigalattopoietica.
MX9203261A (es)	1992-07-01	Nuevas 12-amino-piridazino [4',5':3,4] pirrolo[2,1-a]-isoquinolinas y composiciones farmaceuticas que las contienen.
DE68916472D1 (de)	1994-08-04	Polyäthylen-Zusammensetzung.
ATE82138T1 (de)	1992-11-15	Geregelte verabreichungszusammensetzung.